Monotherapy with immunomodulators (HR 188.09, 95% CI 58.7–601.9), anti-TNFα (HR 4.14, 95% CI 1.5–10.8), and UST (HR 3.32, 95% CI 1.1–9.7) similarly exhibited a positive association with cancer risk. This evidence concerns the gene TNF and cancer.